ClinicalTrials.gg
CompletedNCT05190068Updated Apr 9, 2025

HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

A Phase 1 interventional study of HMPL-760 in B-Cell Non-Hodgkin's Lymphoma, sponsored by Hutchmed. Completed at 22 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-09.

Sponsored by Hutchmed · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
89
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 283 studies in Lymphoma, B-Cell with a site in China — 125 open to participants now, 146 under way, 9 of them phase 3. Lymphoma, B-Cell · China.

Enrollment
54th of 273
89 · median 30
Started
2022
with 24 others
Phase 1
124 of 283
57 open now
Registered
132nd of 283
by date

Among the 283 studies in Lymphoma, B-Cell with a site in China, this one is the 54th largest by enrollment of the 273 interventional ones that give a count, is one of 25 that started in 2022, is one of 124 in phase 1, and was the 132nd registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

125 of the 283 studies in Lymphoma, B-Cell with a site in China are open now. Recruiting first, the newest first:

120 more — sign in →

All 125 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Lymphoma, B-Cell with a site in China, or all of them as a file.
02

Study summary

A Multicenter, Open-label, Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of HMPL-760 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Read the detailed description

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HMPL-760 administered orally in subjects with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL). Patients with relapsed/refractory B-NHL, including chronic lymphocytic leukemia/small cell lymphoma (CLL/SLL), diffuse large B-cell lymphoma (DLBCL), follicular cell lymphoma (FL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and lymphoplasmacytic/macroglobulinemia (LPL/WM).

03

Conditions studied

  • B-Cell Non-Hodgkin's Lymphoma

Browse trials for

Keywords

  • B-Cell Non-Hodgkin's Lymphoma
  • Bruton's tyrosine kinase inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed Form (ICF)
  2. Age ≥18 years
  3. (ECOG) performance status of 0 or 1. In the expansion stage, ECOG performance status 0-2
  4. patients with confirmed lymphoma

    • CLL confirmed by cytology (flow cytometry)
    • LPL/WM diagnosed by relevant tests including serum, bone marrow, and pathological examinations.
  5. Except for CLL and WM, at least one bidimensionally is required by CT scan, which means the largest diameter of lymph node lesions >1.5 cm or extranodal lesions >1.0 cm; For lesions that cannot be well displayed by CT due to anatomical location (such as limb or soft tissue lesions), MRI measurement can be used.
  6. Expected survival longer than 24 weeks

Exclusion criteria

Exclusion Criteria:

Patients who met any of the following criteria are excluded from the study:

  1. Lymphoma patients with central nervous system (CNS) or invasion
  2. Inadequate organ function of liver and kidney
  3. Carcinoma in situ of the breast History of liver disease, including cirrhosis, alcoholism, or currently known active infection with (HIV), virus (HBV), or virus (HCV)
  4. Any anti-tumor therapy including chemotherapy and radiotherapy within 3 weeks prior to the first dose of study drug
  5. Within 7 days or approximately 5 half-lives (whichever is longer) prior to the first dose of the drug, received any or approved small molecule targeted anti-cancer therapies.
  6. Any monoclonal antibody used for anti-tumor therapy within 4 weeks or 2 half-lives prior to the first dose of study drug, whichever is longer
  7. Prior use of any anti-tumor vaccine
  8. Prior administration of radioimmunotherapy within 3 months prior to the first dose of study drug
  9. Any uncontrolled active infection
  10. History of drug-induced interstitial pneumonia
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    Relapsed/refractory B-NHL

    The starting dose of HMPL-760 is initially set as 50 mg, and then the doses of 100 mg, 200 mg, 300 mg, and 400 mg are escalated successively (this dose gradient is assumed). HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles.

    Drug: HMPL-760

Interventions

  • HMPL-760 was administered continuously as a single agent orally every day in sequential 28-day cycles.

06

What researchers measure

Primary outcomes

  1. DLTs

    Number of subjects with Dose Limiting Toxicities (DLTs) with relapsed/refractory B-cell non-Hodgkin's lymphoma relapsed/refractory B-cell non-Hodgkin's lymphoma

    Time frame: Up to 28 days after first dose of study drug.

  2. Safety and Tolerability

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0

    Time frame: Baseline up to the end of study

Secondary outcomes

  1. Objective response rate (ORR)

    Defined as the proportion of patients with CR/Partial response (PR)/CR with incomplete hematologic recovery (CRi)/ partial response with lymphocytosis (PR-L)

    Time frame: Baseline up to 6 months after the last patient was enrolled

  2. Complete response rate (CR rate)

    Defined as the proportion of patients with CR/CRi

    Time frame: Baseline up to 6 months after the last patient was enrolled

  3. Progression-free survival (PFS)

    Defined as the time from the first dose of HMPL-760 to occurrence of Progressive disease (PD) or death, whichever comes first

    Time frame: Baseline up to 6 months after the last patient was enrolled

  4. Time to Response (TTR)

    Defined as the time from the first dose of HMPL-760 to the first objective response

    Time frame: Baseline up to 6 months after the last patient was enrolled

  5. Clinical Benefit Rate (CBR)

    Defined as the proportion of patients with CR/CRi, PR/PR-L and Stable disease (SD)

    Time frame: Baseline up to 6 months after the last patient was enrolled

  6. Duration of Response (DoR)

    Defined as the time from the initial objective response to disease recurrence, progression or death

    Time frame: Baseline up to 6 months after the last patient was enrolled

  7. Overall Survival (OS)

    Defined as the time from the first dose to death due to any cause

    Time frame: Baseline up to 6 months after the last patient was enrolled

07

Study locations

22 sites
  • Beijing Chao-Yang Hospital, Capital Medical University
    Beijing, Beijing, China
  • The First Affiliated Hospital of Xiamen University
    Xiameng, Fujian, China
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong, China
  • Guangxi Medical University cancer Hospital & Guangxi Cancer Institute
    Nanning, Guangxi Zhuang Autonomous Region, China
  • Affiliated Hospital of Chengde Medical University
    Chengde, Hebei, China
  • Henan Cancer Hospital
    Zhengzhou, Henan, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei, China
  • Chenzhou First People's Hospital
    Chenzhou, Hunan, China
  • First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu, China
  • Jiangxi Cancer Hospital
    Nanchang, Jiangxi, China
  • Jilin Cancer Hospital
    Changchun, Jilin, China
  • The Second Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning, China
  • Harbin Medical University Cancer Hospital
    Harbin, Longjiang Hei, China
  • Qilu Hospital of Shandong University
    Jinan, Shandong, China
  • Heping Hospital Affiliated to Changzhi Medical College
    Changzhi, Shanxi, China
  • Shanxi Bethune Hospital
    Taiyuan, Shanxi, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
  • Affiliated Hangzhou First People's Hospital ,Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
  • Chongqing university cancer hospital
    Chongqing, China
  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Jan 2025, 36 months.

Of 90 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's 36 months is below that.

Counting every sponsor, half of 207 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2021
First posted
Jan 13, 2022
StartActual
Jan 4, 2022
Primary completionActual
Jan 27, 2025
CompletionActual
Jan 27, 2025
Last update
Apr 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05190068
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Jan 13, 2022
Start date
Jan 4, 2022
Primary completion
Jan 27, 2025
Completion
Jan 27, 2025
Last update
Apr 9, 2025

Study contacts

Weili Zhao, Ph.D
principal investigator · Shanghai Jiao Tong University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BTK Inhibitor HMPL-760

Start the discussion